Would you rechallenge with cabozantinib in a patient with HCC after the development of a 6 mm gastrohepatic fistula without perforation or communication with the peritoneal cavity?   

This is a tough situation. Based on the package insert for Cabozantinib, it can cause GI fistula and perforation in about 1% of patients and any grade 4 should prompt discontinuation of the drug label. The current gastrohepatic fistula without perforation could lead to recurrent abscesses in the liv...